Full Year 2023 Investor Presentation
28
Investor presentation
Full year 2023
First two human dose initiations with Dicerna in Q4 2022 in line
with ambition presented at Capital Markets Day 2022
First two phase 1 trials in MASH with siRNA technology initiated
Diabetes care
Obesity care
Trial 1
Target: MARC1
Trial 2
Target: LXR(a)
CVD
32 patients
48 patients
MASH
RBD
RED
Other areas
Trial objectives
The trials are investigating safety, tolerability,
pharmacokinetics and pharmacodynamics of
the respective siRNA-based assets
siRNA: Small interfering RNA; MARC1: Mitochondrial amidoxime reducing component 1; LXR(a): Liver X receptor alpha
Novo Nordisk and Dicerna
•
•
After a productive partnership since 2019, Novo Nordisk
acquired Dicerna pharmaceuticals in 2021 for $3.3 bUSD
Integrated into Novo Nordisk and now operates as a
transformational research unit (TRU) responsible for the
siRNA research technology platform
Setup to preserve the agility and speed of a smaller biotech,
while leveraging the scale and experience of a large
pharmaceutical company
Ambition
•
Generate an average of 3 first human dose projects per year
across therapy areas with the siRNA technology platform
Novo NordiskⓇView entire presentation